The American Association of Tissue Banks tissue donor screening for Mycobacterium tuberculosis-Recommended criteria and literature review.
donor eligibility
donor screening
exclusion criteria
tissue transmission
tissue transplantation
tuberculosis
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
09 Jun 2024
09 Jun 2024
Historique:
revised:
12
04
2024
received:
06
03
2024
accepted:
25
04
2024
medline:
9
6
2024
pubmed:
9
6
2024
entrez:
9
6
2024
Statut:
aheadofprint
Résumé
After two multistate outbreaks of allograft tissue-transmitted tuberculosis (TB) due to viable bone, evidence-based donor screening criteria were developed to decrease the risk of transmission to recipients. Exclusionary criteria, commentary, and references supporting the criteria are provided, based on literature search and expert opinion. Both exposure and reactivation risk factors were considered, either for absolute exclusion or for exclusion in combination with multiple risk factors. A criteria subset was devised for tissues containing viable cells. Risk factors for consideration included exposure (e.g., geographic birth and residence, travel, homelessness, incarceration, healthcare, and workplace) and reactivation (e.g., kidney disease, liver disease, history of transplantation, immunosuppressive medications, and age). Additional donor considerations include the possibility of sepsis and chronic illness. Donor screening criteria represent minimal criteria for exclusion and do not completely exclude all possible donor TB risks. Additional measures to reduce transmission risk, such as donor and product testing, are discussed but not included in the recommendations. Careful donor evaluation is critical to tissue safety.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14294Informations de copyright
© 2024 The Authors. Transplant Infectious Disease published by Wiley Periodicals LLC.
Références
Schwartz NG, Hernandez‐Romieu AC, Annambhotla P, et al. Nationwide tuberculosis outbreak in the USA linked to a bone graft product: an outbreak report. Lancet Infect Dis. 2022;22(11):1617‐1625. doi:10.1016/S1473‐3099(22)00425‐X
Wortham JM, Haddad MB, Stewart RJ, et al. Second nationwide tuberculosis outbreak caused by bone allografts containing live cells. MMWR Morb Mortal Wkly Rep. 2024:1385‐1389. Available from: https://www.cdc.gov/mmwr/volumes/72/wr/mm725253a1.htm
American Association of Tissue Banks. Potential mycobacterium tuberculosis transmission through tissue transplantation. AATB Bulletin 21–6. 2021. Accessed January 22, 2024. Available from: https://www.aatb.org/bulletin‐21‐6
American Association of Tissue Banks. Recommendation issued to tissue banks regarding the risk of MTB transmission. AATB Bulletin 22‐2. 2022. Accessed January 22, 2024. Available from: https://www.aatb.org/bulletin‐22‐2
American Association of Tissue Banks. Requirements and recommendations for reducing risk of Mycobacterium tuberculosis transmission. Bulletin 23–6. 2023. Accessed January 22, 2024. Available from: https://www.aatb.org/bulletin‐23‐6
American Association of Tissue Banks [landing page]. 2024. Accessed February 18, 2024. Available from: www.aatb.org
Fishman JA, Greenwald MA, Grossi PA. Transmission of infection with human allografts: essential considerations in donor screening. Clin Infect Dis. 2012;55(5):720‐727. doi:10.1093/cid/cis519
Centers for Disease Control and Prevention (CDC). Update: allograft‐associated bacterial infections–United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51(10):207‐210.
Centers for Disease Control and Prevention (CDC). Invasive Streptococcus pyogenes after allograft implantation–Colorado, 2003. MMWR Morb Mortal Wkly Rep. 2003;52(48):1174‐1176.
Tugwell BD, Patel PR, Williams IT, et al. Transmission of hepatitis C virus to several organ and tissue recipients from an antibody‐negative donor background: although hepatitis c virus (HCV) transmission. Ann Intern Med. 2005;143(9):648‐654.
Centers for Disease Control and Prevention (CDC). Transmission of hepatitis C virus through transplanted organs and tissue–Kentucky and Massachusetts, 2011. MMWR Morb Mortal Wkly Rep. 2011;60(50):1697‐1700.
Food and Drug Administration (US). Human cells, tissues, and cellular and tissue‐based products. 21 Code of Federal Regulations Part 1271. Accessed January 22, 2024. Available from: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm?CFRPart=1271
Food and Drug Administration (US). Guidance for industry: eligibility determination for donors of human cells, tissues, and cellular and tissue‐based products. 2007. Accessed January 22, 2024. Available from: https://www.fda.gov/media/73072/download
American Association of Tissue Banks. Standards for Tissue Banking. 14th ed. American Association of Tissue Banks; 2022.
Greenwald MA, Kuehnert MJ, Fishman JA. Infectious disease transmission during organ and tissue transplantation. Emerg Infect Dis. 2012;18(8):e1. doi:10.3201/eid1808.120277
James J. Tuberculosis transmitted by banked bone. J Bone Joint Surg Br. 1953;35‐B(4):578. doi:10.1302/0301‐620X.35B4.578
Li R, Wilson WW, Schwartz NG, et al. Notes from the field: tuberculosis outbreak linked to a contaminated bone graft product used in spinal surgery — Delaware, March–June 2021. MMWR Morb Mortal Wkly Rep. 2021;70(36):1261‐1263. doi:10.15585/mmwr.mm7036a4
Marshall KE, Free RJ, Filardo TD, et al. Incomplete tissue product tracing during an investigation of a tissue‐derived tuberculosis outbreak. Am J Transplant. 2024;24(1):115‐122. doi:10.1016/j.ajt.2023.09.005
Li R, Deutsch‐Feldman M, Adams T, et al. Transmission of Mycobacterium tuberculosis to healthcare personnel resulting from contaminated bone graft material, United States, June 2021–August 2022. Clin Infect Dis. 2023;76(10):1847‐1849. doi:10.1093/cid/ciad029
Khanna SK, Ross JK, Monro JL. Homograft aortic valve replacement: seven years’ experience with antibiotic‐treated valves. Thorax. 1981;36(5):330‐337.
Anyanwu CH, Nassau E, Yacoub M. Miliary tuberculosis following homograft valve replacement. Thorax. 1976;31(1):101‐106. doi:10.1136/thx.31.1.101
Warwick RM, Magee JG, Leeming JP, et al. Mycobacteria and allograft heart valve banking: an international survey. J Hosp Infect. 2008;68(3):255‐261. doi:10.1016/j.jhin.2007.11.019
Wortham JM, Haddad MB, Stewart RJ, et al. Second nationwide tuberculosis outbreak caused by bone allografts containing live cells — United States, 2023. MMWR Morb Mortal Wkly Rep. 2024;72(5253):1385‐1389. doi:10.15585/mmwr.mm725253a1
Subramanian AK, Theodoropoulos NM. Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13513. doi:10.1111/ctr.13513
Jones JM, Vikram HR, Lauzardo M, et al. Tuberculosis transmission across three states: the story of a solid organ donor born in an endemic country, 2018. Transpl Infect Dis. 2020;22(6):e13357. doi:10.1111/tid.13357
Morris MI, Daly JS, Blumberg E, et al. Diagnosis and management of tuberculosis in transplant donors: a donor‐derived infections consensus conference report. Am J Transplant. 2012;12:2288‐2300. doi:10.1111/j.1600‐6143.2012.04205.x
Malinis M, LaHoz RM, Vece G, et al. Donor‐derived tuberculosis among solid organ transplant recipients in the United States—2008 to 2018. Transpl Infect Dis. 2022;24(2):e13800. doi:10.1111/tid.13800
Al‐Anazi KA, Al‐Jasser AM, Alsaleh K. Infections caused by Mycobacterium tuberculosis in recipients of hematopoietic stem cell transplantation. Front Oncol. 2014;4:231. doi:10.3389/fonc.2014.00231
Bergeron A. Tuberculosis in allogeneic haematopoietic stem cell transplantation: so many unresolved questions! Bone Marrow Transplant. 2021;56(9):2050‐2051. doi:10.1038/s41409‐021‐01381‐z
Catedral EJ, Santos RE, Padilla MDB, Fajardo‐Ang C. Detection of Mycobacterium tuberculosis in corneas from donors with active tuberculosis disease through polymerase chain reaction and culture. Br J Ophthalmol. 2010;94(7):894‐897. doi:10.1136/bjo.2008.153270
Ferraris D, Miggiano R, Rossi F, Rizzi M. Mycobacterium tuberculosis molecular determinants of infection, survival strategies, and vulnerable targets. Pathogens. 2018;7(1):17. doi:10.3390/pathogens7010017
de Martino M, Lodi L, Galli L, Chiappini E. Immune response to Mycobacterium tuberculosis: a narrative review. Front Pediatr. 2019;7:350. doi:10.3389/fped.2019.00350
Shah M, Dorman SE. Latent tuberculosis infection. N Engl J Med. 2021;385(24):2271‐2280. doi:10.1056/NEJMcp2108501
Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers. Publication Number 22–0468. 2020. Accessed January 22, 2024. Available from: https://www.cdc.gov/tb/publications/ltbi/pdf/LTBIbooklet508.pdf
Nguyen MVH, Levy NS, Ahuja SD, Trieu L, Proops DC, Achkar JM. Factors associated with sputum culture‐negative vs culture‐positive diagnosis of pulmonary tuberculosis. JAMA Netw Open. 2019;2(2):e187617. doi:10.1001/jamanetworkopen.2018.7617
World Health Organization. Tuberculosis fact sheet. 2024.
World Health Organization (WHO). Global tuberculosis report 2022. 2022. Accessed January 22, 2024. Available from: https://www.who.int/teams/global‐tuberculosis‐programme/tb‐reports/global‐tuberculosis‐report‐2022
Centers for Disease Control and Prevention, Division of Tuberculosis Elimination NC for HVHS and TPC for DC and P. Table 1. Tuberculosis cases, incidence rates per 100,000 population, deaths, death rates per 100,000 population, and percentage change: United States, 1953–2022. Reported tuberculosis in the United States, 2022. 2023. Accessed January 29, 2024. Available from: https://www.cdc.gov/tb/statistics/reports/2022/table1.htm?CDC_AA_refVal=%3A%2F%2Fwww.cdc.gov%2Ftb%2Fstatistics%2Ftbcases.htm
World Health Organization. Global tuberculosis report application. 2022. Accessed January 22, 2024. Available from: https://worldhealthorg.shinyapps.io/tb_profiles/?_inputs_&entity_type=%22country%22&iso2=%22AF%22&lan=%22EN%22
Centers for Disease Control and Prevention, Division of Tuberculosis Elimination NC for HVHS and TPC for DC and P. Reported tuberculosis in the United States, 2022. 2023. Accessed January 29, 2024. Available from: https://www.cdc.gov/tb/statistics/reports/2022/national_data.htm
Zimmer AJ, Klinton JS, Oga‐Omenka C, et al. Tuberculosis in times of COVID‐19. J Epidemiol Commun Health (1978). 2022;76(3):310‐316. doi:10.1136/jech‐2021‐217529
Hogan AB, Jewell BL, Sherrard‐Smith E, et al. Potential impact of the COVID‐19 pandemic on HIV, tuberculosis, and malaria in low‐income and middle‐income countries: a modelling study. Lancet Glob Health. 2020;8(9):e1132‐e1141. doi:10.1016/S2214‐109X(20)30288‐6
Marais BJ, Gie RP, Schaaf HS, et al. The clinical epidemiology of childhood pulmonary tuberculosis: a critical review of literature from the pre‐chemotherapy era. Int J Tuberc Lung Dis. 2004;8(3):278‐285.
Das B, Kashino SS, Pulu I, et al. CD271+ bone marrow mesenchymal stem cells may provide a niche for dormant mycobacterium tuberculosis. Sci Transl Med. 2013;5(170):170ra13. doi:10.1126/scitranslmed.3004912
Kim JW, Bowman K, Nazareth J, et al. PET‐CT‐guided characterisation of progressive, preclinical tuberculosis infection and its association with low‐level circulating Mycobacterium tuberculosis DNA in household contacts in Leicester, UK: a prospective cohort study. Lancet Microbe. 2024;5(2):e119‐e130. doi:10.1016/S2666‐5247(23)00289‐6
Heemskerk D, Caws M, Marais B, Farrar J. Tuberculosis in Adults and Children. 1st ed. Springer Cham; 2015.
Miggiano R, Rizzi M, Ferraris DM. Mycobacterium tuberculosis pathogenesis, infection prevention and treatment. Pathogens. 2020;9(5):385. doi:10.3390/pathogens9050385
Peto HM, Pratt RH, Harrington TA, LoBue PA, Armstrong LR. Epidemiology of extrapulmonary tuberculosis in the United States, 1993–2006. Clin Infect Dis. 2009;49(9):1350‐1357.
Schildknecht KR, Pratt RH, Feng PJI, Price SF, Self JL. Morbidity and mortality weekly report tuberculosis‐United States. 2022. Available from: https://www.census.gov/programs‐surveys/popest/data/tables.html;
World Health Organization. Global tuberculosis report 2023. 2023. Accessed January 22, 2024. Available from: https://www.who.int/publications/i/item/9789240083851
Lewinsohn DM, Leonard MK, Lobue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):e1‐e33. doi:10.1093/cid/ciw694
Centers for Disease Control and Prevention. Tuberculosis technical instructions for panel physicians. Accessed January 22, 2024. Available from: https://www.cdc.gov/immigrantrefugeehealth/pdf/TB‐panel‐tech‐instructions‐h.pdf
Boardman NJ, Moore T, Freiman J, et al. Pulmonary tuberculosis disease among immigrant detainees: rapid disease detection, high prevalence of asymptomatic disease, and implications for tuberculosis prevention. Clin Infect Dis. 2021;73(1):115‐120. doi:10.1093/cid/ciaa434
Jereb J. Tuberculosis. In: CDC Yellow Book: Travel‐associated infections & diseases. Centers for Disease Control and Prevention. 2024. Accessed January 22, 2024. Available from: https://wwwnc.cdc.gov/travel/yellowbook/2024/infections‐diseases/tuberculosis
Centers for Disease Control and Prevention. Core curriculum on tuberculosis: what the clinician should know. 2021. Accessed January 22, 2024. Available from: https://www.cdc.gov/tb/education/corecurr/pdf/CoreCurriculumTB‐508.pdf
Cobelens FGJ, van Deutekom H, Draayer‐Jansen IWE, et al. Association of tuberculin sensitivity in Dutch adults with history of travel to areas of with a high incidence of tuberculosis. Clin Infect Dis. 2001;33(3):300‐304. doi:10.1086/321882
Centers for Disease Control and Prevention (CDC). Tuberculosis transmission in a homeless shelter population–New York, 2000–2003. MMWR Morb Mortal Wkly Rep. 2005;54(6):149‐152.
Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Reported tuberculosis in the United States, 2021. 2022. Accessed January 30, 2024. Available from: https://www.cdc.gov/tb/statistics/reports/2021/risk_factors.htm
Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. Table 42. Tuberculosis cases and percentages by social risk factors, ages ≥ 14 years: reporting areas, 2021. Reported tuberculosis in the United States, 2021. 2022. Accessed January 30, 2024. Available from: https://www.cdc.gov/tb/statistics/reports/2021/table42.htm
Bamrah S, Yelk Woodruff RS, Powell K, Ghosh S, Kammerer JS, Haddad MB. Tuberculosis among the homeless, United States, 1994–2010. Int J Tuberc Lung Dis. 2013;17(11):1414‐1419. doi:10.5588/ijtld.13.0270
Tankimovich M. Barriers to and interventions for improved tuberculosis detection and treatment among homeless and immigrant populations: a literature review. J Commun Health Nurs. 2013;30(2):83‐95. doi:10.1080/07370016.2013.778723
Khan K, Rea E, Mcdermaid C, et al. Active tuberculosis among homeless persons, Toronto, Ontario, Canada, 1998–2007. Emerg Infect Dis. 2011;17(3):357‐365. doi:10.3201/eid1703.100833
Moss AR, Hahn JA, Tulsky JP, Daley CL, Small PM, Hopewell PC. Tuberculosis in the homeless: a prospective study. 2000. Available from: www.atsjournals.org
Powell KM, VanderEnde DS, Holland DP, et al. Outbreak of drug‐resistant mycobacterium tuberculosis among homeless people in Atlanta, Georgia, 2008–2015. Public Health Rep. 2017;132(2):231‐240. doi:10.1177/0033354917694008
McAdam JM, Brickner PW, Scharer LL, Crocco JA, Duff AE. The spectrum of tuberculosis in a New York City men's shelter clinic (1982‐1988). Chest. 1990;97(4):798‐805. doi:10.1378/chest.97.4.798
Martinez L, Warren JL, Harries AD, et al. Global, regional, and national estimates of tuberculosis incidence and case detection among incarcerated individuals from 2000 to 2019: a systematic analysis. Lancet Public Health. 2023;8(7):e511‐e519. doi:10.1016/S2468‐2667(23)00097‐X
Grenzel ML, Grande AJ, Paniago AMM, Pompilio MA, de Oliveira SM do VL, Trajman A. Tuberculosis among correctional facility workers: a systematic review and meta‐analysis. PLoS One. 2018;13(11):e0207400. doi:10.1371/journal.pone.0207400
Placeres AF, de Almeida Soares D, Delpino FM, et al. Epidemiology of TB in prisoners: a metanalysis of the prevalence of active and latent TB. BMC Infect Dis. 2023;23(1):20. doi:10.1186/s12879‐022‐07961‐8
Cords O, Martinez L, Warren JL, et al. Incidence and prevalence of tuberculosis in incarcerated populations: a systematic review and meta‐analysis. Lancet Public Health. 2021;6(5):e300‐e308. doi:10.1016/S2468‐2667(21)00025‐6
Lambert LA, Armstrong LR, Lobato MN, Ho C, France AM, Haddad MB. Tuberculosis in jails and prisons: United States, 2002−2013. Am J Public Health. 2016;106(12):2231‐2237. doi:10.2105/AJPH.2016.303423
Centers for Disease Control and Prevention, Division of Tuberculosis Elimination. TB and people living in correctional facilities in the United States. Tuberculosis. 2022. Accessed January 29, 2024. Available from: https://www.cdc.gov/tb/topic/populations/correctional/default.htm
Stewart RJ, Raz KM, Burns SP, et al. Tuberculosis outbreaks in state prisons, United States, 2011–2019. Am J Public Health. 2022;112(8):1170‐1179. doi:10.2105/AJPH.2022.306864
Mitchell CS, Gershon RRM, Lears MK, et al. Risk of tuberculosis in correctional healthcare workers. J Occup Environ Med. 2005;47(6):580‐586. doi:10.1097/01.jom.0000161738.88347.e4
Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. Health Care Personnel: recommendations from the National Tuberculosis Controllers Association and CDC. 2019. Available from: https://academic.oup.com/cid/article/64/2/111/2811357
Lambert LA, Pratt RH, Armstrong LR, Haddad MB. Tuberculosis among healthcare workers, United States, 1995–2007. Infect Control Hosp Epidemiol. 2012;33(11):1126‐1131. doi:10.1086/668016
Daniel T. Institute of Medicine (US) Committee on Regulating Occupational Exposure to Tuberculosis. Tuberculosis in the Workplace. National Academies Press; 2001.
Centers for Disease Control and Prevention. Prevention and control of tuberculosis in facilities providing long‐term care to the elderly. Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR Recomm Rep. 1990;30(RR‐10):7‐20.
Khan A, Rebhan A, Seminara D, Szerszen A. Enduring Challenge of Latent Tuberculosis in Older Nursing Home Residents: A Brief Review. J Clin Med Res. 2019;11(6):385‐390. doi:10.14740/jocmr3763
Centers for Disease Control and Prevention. Prevention and control of tuberculosis in facilities providing long‐term care to the elderly. Recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR Recomm Rep. 1990;39(RR‐10):7‐13.
Chitnis AS, Robsky K, Schecter GF, Westenhouse J, Barry PM. Trends in Tuberculosis Cases Among Nursing Home Residents, California, 2000 to 2009. J Am Geriatr Soc. 2015;63(6):1098‐1104. doi:10.1111/jgs.13437
Bikbov B, Purcell CA, Levey AS, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet North Am Ed. 2020;395(10225):709‐733. doi:10.1016/S0140‐6736(20)30045‐3
Romanowski K, Clark EG, Levin A, Cook VJ, Johnston JC. Tuberculosis and chronic kidney disease: an emerging global syndemic. Kidney Int. 2016;90(1):34‐40. doi:10.1016/j.kint.2016.01.034
Cheng KC, Liao KF, Lin CL, Liu CS, Lai SW. Chronic kidney disease correlates with increased risk of pulmonary tuberculosis before initiating renal replacement therapy. Medicine. 2018;97(39):e12550. doi:10.1097/MD.0000000000012550
Park S, Lee S, Kim Y, et al. Association of CKD with incident tuberculosis. Clin J Am Soc Nephrol. 2019;14(7):1002‐1010. doi:10.2215/CJN.14471218
Yan M, Puyat JH, Shulha HP, Clark EG, Levin A, Johnston JC. Risk of tuberculosis associated with chronic kidney disease: a population‐based analysis. Nephrol Dial Transplant. 2021;37(1):197‐198. doi:10.1093/ndt/gfab222
James MT, Laupland KB, Tonelli M, et al. Risk of bloodstream infection in patients with chronic kidney disease not treated with dialysis. Arch Intern Med. 2008;168(21):2333. doi:10.1001/archinte.168.21.2333
Dalrymple LS, Katz R, Kestenbaum B, et al. The risk of infection‐related hospitalization with decreased kidney function. Am J Kidney Dis. 2012;59(3):356‐363. doi:10.1053/j.ajkd.2011.07.012
McDonald HI, Thomas SL, Millett ERC, Nitsch D. CKD and the risk of acute, community‐acquired infections among older people with diabetes mellitus: a retrospective cohort study using electronic health records. Am J Kidney Dis. 2015;66(1):60‐68. doi:10.1053/j.ajkd.2014.11.027
Ishigami J, Grams ME, Chang AR, Carrero JJ, Coresh J, Matsushita K. CKD and risk for hospitalization with infection: The Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2017;69(6):752‐761. doi:10.1053/j.ajkd.2016.09.018
Espi M, Koppe L, Fouque D, Thaunat O. Chronic kidney disease‐associated immune dysfunctions: impact of protein‐bound uremic retention solutes on immune cells. Toxins. 2020;12(5):300. doi:10.3390/toxins12050300
Luczynski P, Holmes T, Romanowski K, et al. Risk of tuberculosis disease in people with chronic kidney disease without kidney failure: a systematic review and meta‐analysis. Clin Infect Dis. 2023;77(8):1194‐1200. doi:10.1093/cid/ciad364
Campo S, Lacquaniti A, Trombetta D, Smeriglio A, Monardo P. Immune system dysfunction and inflammation in hemodialysis patients: two sides of the same coin. J Clin Med. 2022;11(13):3759. doi:10.3390/jcm11133759
Betjes MGH. Immune cell dysfunction and inflammation in end‐stage renal disease. Nat Rev Nephrol. 2013;9(5):255‐265. doi:10.1038/nrneph.2013.44
Ducloux D, Legendre M, Bamoulid J, Saas P, Courivaud C, Crepin T. End‐stage renal disease‐related accelerated immune senescence: is rejuvenation of the immune system a therapeutic goal? Front Med. 2021;8:720402. doi:10.3389/fmed.2021.720402
Centers for Disease Control and Prevention (CDC). Tuberculosis transmission in a renal dialysis center–Nevada, 2003. MMWR Morb Mortal Wkly Rep. 2004;53(37):873‐875.
Linquist JA, Rosaia CM, Riemer B, Heckman K, Alvarez F. Tuberculosis exposure of patients and staff in an outpatient hemodialysis unit. Am J Infect Control. 2002;30(5):307‐310. doi:10.1067/mic.2002.123394
Centers for Disease Control and Prevention. Dialysis safety: guidelines, recommendations and resources. 2017. Accessed January 25, 2024. Available from: https://www.cdc.gov/dialysis/guidelines/index.html
Centers for Disease Control and Prevention. Dialysis‐related outbreaks: current. dialysis safety. 2020. Accessed January 25, 2024. Available from: https://www.cdc.gov/dialysis/reports‐news/outbreaks.html
World Health Organization. Global tuberculosis report 2021. 2021. Accessed August 29, 2023. Available from: https://www.who.int/publications/digital/global‐tuberculosis‐report‐2021/featured‐topics/tb‐diabetes
Centers for Disease Control and Prevention. TB and diabetes. 2022. Accessed September 5, 2023. Available from: doi:10.3390/jcm8122219
van Crevel R, Critchley JA. The interaction of diabetes and tuberculosis: translating research to policy and practice. Trop Med Infect Dis. 2021;6(1):8. doi:10.3390/tropicalmed6010008
Yorke E, Atiase Y, Akpalu J, Sarfo‐Kantanka O, Boima V, Dey ID. The bidirectional relationship between tuberculosis and diabetes. Tuberc Res Treat. 2017;2017:1‐6. doi:10.1155/2017/1702578
Bisht MK, Dahiya P, Ghosh S, Mukhopadhyay S. The cause–effect relation of tuberculosis on incidence of diabetes mellitus. Front Cell Infect Microbiol. 2023;13:1134036. doi:10.3389/fcimb.2023.1134036
Lu P, Zhang Y, Liu Q, et al. Association of BMI, diabetes, and risk of tuberculosis: a population‐based prospective cohort. Int J Infect Dis. 2021;109:168‐173. doi:10.1016/j.ijid.2021.06.053
MAGEE MJ, FOOTE M, RAY SM, GANDHI NR, KEMPKER RR. Diabetes mellitus and extrapulmonary tuberculosis: site distribution and risk of mortality. Epidemiol Infect. 2016;144(10):2209‐2216. doi:10.1017/S0950268816000364
Lönnroth K, Roglic G, Harries AD. Improving tuberculosis prevention and care through addressing the global diabetes epidemic: from evidence to policy and practice. Lancet Diabetes Endocrinol. 2014;2(9):730‐739. doi:10.1016/S2213‐8587(14)70109‐3
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):e152. doi:10.1371/journal.pmed.0050152
Kang JY, Han K, Lee SH, Kim MK. Diabetes severity is strongly associated with the risk of active tuberculosis in people with type 2 diabetes: a nationwide cohort study with a 6‐year follow‐up. Respir Res. 2023;24(1):110. doi:10.1186/s12931‐023‐02414‐5
Al‐Rifai RH, Pearson F, Critchley JA, Abu‐Raddad LJ. Association between diabetes mellitus and active tuberculosis: a systematic review and meta‐analysis. PLoS One. 2017;12(11):e0187967. doi:10.1371/journal.pone.0187967
Martinez N, Kornfeld H. Diabetes and immunity to tuberculosis. Eur J Immunol. 2014;44(3):617‐626. doi:10.1002/eji.201344301
Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. PLoS Med. 2008;5(7):1091‐1101. doi:10.1371/journal.pmed.0050152
Ferlita S, Yegiazaryan A, Noori N, et al. Type 2 diabetes mellitus and altered immune system leading to susceptibility to pathogens, especially Mycobacterium tuberculosis. J Clin Med. 2019;8(12):2219. doi:10.3390/jcm8122219
Baker MA, Harries AD, Jeon CY, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81. doi:10.1186/1741‐7015‐9‐81
Tegegne BS, Mengesha MM, Teferra AA, Awoke MA, Habtewold TD. Association between diabetes mellitus and multi‐drug‐resistant tuberculosis: evidence from a systematic review and meta‐analysis. Syst Rev. 2018;7(1):161. doi:10.1186/s13643‐018‐0828‐0
Magee MJ, Khakharia A, Gandhi NR, et al. Increased risk of incident diabetes among individuals with latent tuberculosis infection. Diabetes Care. 2022;45(4):880‐887. doi:10.2337/dc21‐1687
Eckold C, Kumar V, Weiner J, et al. Impact of intermediate hyperglycemia and diabetes on immune dysfunction in tuberculosis. Clin Infect Dis. 2021;72(1):69‐78. doi:10.1093/cid/ciaa751
Antonio‐Arques V, Caylà JA, Real J, et al. Glycemic control and the risk of tuberculosis in patients with diabetes: a cohort study in a Mediterranean city. Front Public Health. 2022;10:1017024. doi:10.3389/fpubh.2022.1017024
Noor MT, Manoria P. Immune dysfunction in cirrhosis. J Clin Transl Hepatol. 2017;5(1):50‐58. doi:10.14218/JCTH.2016.00056
Albillos A, Martin‐Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez‐Mon M. Cirrhosis‐associated immune dysfunction. Nat Rev Gastroenterol Hepatol. 2022;19(2):112‐134. doi:10.1038/s41575‐021‐00520‐7
Sipeki N, Antal‐Szalmas P, Lakatos PL, Papp M. Immune dysfunction in cirrhosis. World J Gastroenterol. 2014;20(10):2564. doi:10.3748/wjg.v20.i10.2564
Wilde B, Katsounas A. Immune dysfunction and albumin‐related immunity in liver cirrhosis. Mediat Inflamm. 2019;2019:1‐9. doi:10.1155/2019/7537649
Irvine KM, Ratnasekera I, Powell EE, Hume DA. Causes and consequences of innate immune dysfunction in cirrhosis. Front Immunol. 2019;10:293. doi:10.3389/fimmu.2019.00293
Liu Y Bin, Chen MK. Epidemiology of liver cirrhosis and associated complications: current knowledge and future directions. World J Gastroenterol. 2022;28(41):5910‐5930. doi:10.3748/wjg.v28.i41.5910
Lin YT, Wu PH, Lin CY, et al. Cirrhosis as a risk factor for tuberculosis infection—a nationwide longitudinal study in Taiwan. Am J Epidemiol. 2014;180(1):103‐110. doi:10.1093/aje/kwu095
Thulstrup AM, Mølle I, Svendsen N, Sørensen HT. Incidence and prognosis of tuberculosis in patients with cirrhosis of the liver. A Danish nationwide population based study. Epidemiol Infect. 2000;124(2):221‐225. doi:10.1017/S0950268899003593
Cho Y, Lee SM, Yoo C, et al. Clinical characteristics of tuberculosis in patients with liver cirrhosis. Respirology. 2007;12(3):401‐405. doi:10.1111/j.1440‐1843.2007.01069.x
Sharma P, Tyagi P, Singla V, Bansal N, Kumar A, Arora A. Clinical and biochemical profile of tuberculosis in patients with liver cirrhosis. J Clin Exp Hepatol. 2015;5(1):8‐13. doi:10.1016/j.jceh.2015.01.003
Poplin V, Harbaugh B, Salathe M, Bahr NC. Miliary tuberculosis in a patient with end‐stage liver disease. Cleve Clin J Med. 2020;87(10):590‐593. doi:10.3949/ccjm.87a.19143
Wigger GW, Bouton TC, Jacobson KR, Auld SC, Yeligar SM, Staitieh BS. The impact of alcohol use disorder on tuberculosis: a review of the epidemiology and potential immunologic mechanisms. Front Immunol. 2022;13. doi:10.3389/fimmu.2022.864817
Lau A, von Dossow V, Sander M, MacGuill M, Lanzke N, Spies C. Alcohol use disorder and perioperative immune dysfunction. Anesth Analg. 2009;108(3):916‐920. doi:10.1213/ane.0b013e318193fd89
Pasala S, Barr T, Messaoudi I. Impact of alcohol abuse on the adaptive immune system. Alcohol Res. 2015;37(2):185‐197.
Mason CM, Dobard E, Zhang P, Nelson S. Alcohol exacerbates murine pulmonary tuberculosis. Infect Immun. 2004;72(5):2556‐2563. doi:10.1128/IAI.72.5.2556‐2563.2004
Classen CN, Warren R, Richardson M, et al. Impact of social interactions in the community on the transmission of tuberculosis in a high incidence area. Thorax. 1999;54(2):136‐140. doi:10.1136/thx.54.2.136
Imtiaz S, Shield KD, Roerecke M, Samokhvalov A V., Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta‐analyses and burden of disease. Eur Respir J. 2017;50(1):1700216. doi:10.1183/13993003.00216‐2017
Lönnroth K, Williams BG, Stadlin S, Jaramillo E, Dye C. Alcohol use as a risk factor for tuberculosis – a systematic review. BMC Public Health. 2008;8(1):289. doi:10.1186/1471‐2458‐8‐289
Rehm J, Samokhvalov A V, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). a systematic review. BMC Public Health. 2009;9(1):450. doi:10.1186/1471‐2458‐9‐450
Singh N, Limaye AP. Infections in solid‐organ transplant recipients. In: Bennett JE, Dolin R, Blaser MJ, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2015:3440‐3452. doi:10.1016/B978‐1‐4557‐4801‐3.00313‐1
Roberts MB, Fishman JA. Immunosuppressive agents and infectious risk in transplantation: managing the “net state of immunosuppression.” Clin Infect Dis. 2021;73(7):e1302‐e1317. doi:10.1093/cid/ciaa1189
Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40(4):581‐587. doi:10.1086/427692
Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis. 2010;12(2):106‐112. doi:10.1111/j.1399‐3062.2009.00475.x
Morales P, Briones A, Torres JJ, Solé A, Pérez D, Pastor A. Pulmonary tuberculosis in lung and heart–lung transplantation: fifteen years of experience in a single center in Spain. Transplant Proc. 2005;37(9):4050‐4055. doi:10.1016/j.transproceed.2005.09.144
Torre‐Cisneros J, Doblas A, Aguado JM, et al. Tuberculosis after solid‐organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) Cohort. Clin Infect Dis. 2009;48(12):1657‐1665. doi:10.1086/599035
Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases. Clin Transplant. 2018;32(6):e13259. doi:10.1111/ctr.13259
Subramanian AK. Tuberculosis in solid organ transplant candidates and recipients. Curr Opin Infect Dis. 2014;27(4):316‐321. doi:10.1097/QCO.0000000000000082
García‐Elorriaga G, Rey‐Pineda G. Tuberculosis and hematopoietic stem cell transplant: review of a difficult and often underestimated problem. World J Clin Infect Dis. 2013;3(4):70‐78.
Lorenzetti R, Zullo A, Ridola L, et al. Higher risk of tuberculosis reactivation when anti‐TNF is combined with immunosuppressive agents: A systematic review of randomized controlled trials. Ann Med. 2014;46(7):547‐554. doi:10.3109/07853890.2014.941919
Rahier JF, Magro F, Abreu C, et al. Second European evidence‐based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8(6):443‐468. doi:10.1016/j.crohns.2013.12.013
Bumbacea D, Arend SM, Eyuboglu F, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40(4):990‐1013. doi:10.1183/09031936.00000712
Caraux‐Paz P, Diamantis S, de Wazières B, Gallien S. Tuberculosis in the Elderly. J Clin Med. 2021;10(24):5888. doi:10.3390/jcm10245888
Wu IL, Chitnis AS, Jaganath D. A narrative review of tuberculosis in the United States among persons aged 65 years and older. J Clin Tuberc Other Mycobact Dis. 2022;28:100321. doi:10.1016/j.jctube.2022.100321
Dewar S, Suh T. Latent tuberculosis infection: successful screening and treatment of older adults in a program of all‐inclusive care for the elderly (PACE). 2018. Accessed January 22, 2024. Available from: https://www.hmpgloballearningnetwork.com/site/altc/article/latent‐tuberculosis‐infection‐successful‐screening‐and‐treatment‐older‐adults‐program‐all
Centers for Disease Control and Prevention. TB elimination interferon‐gamma release assays (IGRAs)—blood tests for TB infection. Accessed January 22, 2024. Available from: https://www.cdc.gov/tb/publications/factsheets/testing/igra.pdf
Pai M, Zwerling A, Menzies D. Systematic review: T‐cell–based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008;149(3):177. doi:10.7326/0003‐4819‐149‐3‐200808050‐00241
Campelo TA, Cardoso de Sousa PR, Nogueira L de L, Frota CC, Zuquim Antas PRss. Revisiting the methods for detecting Mycobacterium tuberculosis: what has the new millennium brought thus far? Access Microbiol. 2021;3(8). doi:10.1099/acmi.0.000245
World Health Organization. Module 3: diagnosis. In: World Health Organization, ed. WHO Operational Handbook on Tuberculosis. World Health Organization; 2022.
Sester M, Sotgiu G, Lange C, et al. Interferon‐gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta‐analysis. Eur Respir J. 2011;37(1):100‐111. doi:10.1183/09031936.00114810
Pai M, Sotgiu G. Diagnostics for latent TB infection: Incremental, not transformative progress. Eur Respir J. 2016;47(3):704‐706. doi:10.1183/13993003.01910‐2015
Tabarsi P, Yousefzadeh A, Najafizadeh K, et al. Performance of QuantiFERON TB gold test in detecting latent tuberculosis infection in brain‐dead organ donors in Iran: a brief report. Saudi J Kidney Dis Transpl. 2014;25(6):1240‐1243.
Schmidt T, Schub D, Wolf M, et al. Comparative analysis of assays for detection of cell‐mediated immunity toward cytomegalovirus and M. tuberculosis in samples from deceased organ donors. Am J Transplant. 2014;14(9):2159‐2167. doi:10.1111/ajt.12787
Lange B, Vavra M, Kern W V., Wagner D. Indeterminate results of a tuberculosis‐specific interferon‐γ release assay in immunocompromised patients. Eur Respir J. 2010;35(5):1179‐1182. doi:10.1183/09031936.00122109
Huang CT, Ruan SY, Tsai YJ, et al. Effects of acute critical illnesses on the performance of interferon‐gamma release assay. Sci Rep. 2016;6:19972. doi:10.1038/srep19972
Jain AK, Rajasekaran S, Jaggi KR, Myneedu VP. Tuberculosis of the Spine. J Bone Joint Surg. 2020;102(7):617‐628. doi:10.2106/JBJS.19.00001
Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus definitions for sepsis and septic shock (Sepsis‐3). JAMA. 2016;315(8):801. doi:10.1001/jama.2016.0287
McDermott K, Roemer M. Most frequent principal diagnoses for inpatient stays in U.S. Hospitals, 2018. Healthcare cost and utilization project (HCUP) statistical briefs [Internet]. 2021. Accessed January 29, 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK573113/
Gupta S, Sakhuja A, Kumar G, McGrath E, Nanchal RS, Kashani KB. Culture‐negative severe sepsis. Chest. 2016;150(6):1251‐1259. doi:10.1016/j.chest.2016.08.1460
Fortin M, Soubhi H, Hudon C, Bayliss EA, van den Akker M. Multimorbidity's many challenges. BMJ. 2007;334(7602):1016‐1017. doi:10.1136/bmj.39201.463819.2C
Iezzoni LI, Heeren T, Foley SM, Daley J, Hughes J, Coffman GA. Chronic conditions and risk of in‐hospital death. Health Serv Res. 1994;29(4):435‐460.
Centers for Disease Control and Prevention. Recommended adult immunization schedule, United States 2024. 2024. Accessed January 29, 2024. Available from: https://www.cdc.gov/vaccines/schedules/downloads/adult/adult‐combined‐schedule.pdf
Heck E, Corder V, Urban J, Petroll M, Timmons W, Cavanaugh D. Risk assessment in deferred and recovered donors. Cell Tissue Bank. 2021;22(4):623‐629. doi:10.1007/s10561‐021‐09909‐9
Greenwald MA, Kerby S, Francis K, et al. Detection of human immunodeficiency virus, hepatitis C virus, and hepatitis B virus in postmortem blood specimens using infectious disease assays licensed for cadaveric donor screening. Transpl Infect Dis. 2018;20(1). doi:10.1111/tid.12825